The red blood cells are removed by using the difference in osmotic pressure, and then the white blood cells are identified by specific antibodies and removed using the exclusively licensed PowerMagTM magnetic column. For the products after the above negative screening, the system will automatically perform immunofluorescence staining and fully automatic microscopy photography, and finally the circulating tumor cells will be interpreted by the AI imaging system.
1. Negative selection
2. Convenient testing with only 2ml blood sample
3. Next-day results available
4. Recognized by the National Innovation Award
5. Intact and live CTCs can be obtained
6. 4 samples in parallel (8 samples/day)
7. Modules integration:
8. Customization:
9. Fully automated process:
Incorporating CTCs counts into the current tumor markers could provide a cancer risk index before the tumor is detected by imaging.
Spillover insurance policyholders have a more comprehensive coverage through CTC detection before or after an insurance claim.
CTC detection could be used for early cancer diagnosis to assess cancer risk.
Tumor response could be evaluated by monitoring the CTC status before and after a drug treatment
Genome sequencing of CTCs could provide insights into selecting the optimal drugs for chemotherapy and targeted therapy
Cancer patients could follow up on CTC counts regularly to evaluate whether or notthe cancer has recurred
Itcan Biotech Co., Ltd. passed the ISO 9001 quality management system certification
Copyright © 2025 Itcan Biotech All Rights Reserved
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, you agree that your information will be combined with that of other users.